quartr
OPK: Q2 2026 delivered higher revenue, improved margins, and raised full-year guidance amid pipeline advances
Q2 2026 saw improved profitability, strong cash reserves, and pipeline progress, with revenue rising to $163.6M and operating loss narrowing to $7M. Diagnostics and pharma segments both improved, while guidance for 2026 was raised on the back of robust product and partnership revenue.Based on Opko…